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PFO and the Heart
More Than Meets the Eye!*
Y. Chandrashekhar, MD, DM
Minneapolis, MinnesotaKnowledge and timber shouldn’t be much used till they
are seasoned.
—Oliver Wendell Holmes (1)
As with many things in evolution, some structure or
physiology that is beneficial during development can
be detrimental at a later period. Thus, a patent
foramen ovale (PFO), a cornerstone of embryonic
circulation, can have undesirable consequences if it
continues to be patent, as is the case in up to 25% of
normal adults. A large body of circumstantial evidence
See page 833
including epidemiologic association, case-control
series, and rare reports that have shown an actual
embolus traversing the PFO links PFO to crypto-
genic strokes (2). Much of this evidence, however,
is only of the suggestive variety. Given the difficulty
in generating clearly definitive data, a lot of the
addition to the literature has been just more data of
the same kind. The article by Wöhrle et al. (3) in
this issue of iJACC, although in the same vein, takes
a novel detour and adds important information.
They studied left ventricular late gadolinium
enhancement (LGE) on cardiac magnetic reso-
nance (CMR) in 74 patients with a cryptogenic
stroke, a PFO, and no history of coronary artery
disease (CAD). Of these patients, 10% had LGE,
involving a small amount of myocardium (7%), and
the presence of LGE did not affect left ventricular
size or function. Occlusive CAD was excluded in
7 of 8 patients with LGE. Coronary microemboli-
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
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has no relationships to disclose.zation often results in small foci of focal mid-
myocardial LGE (4), depending on particle size.
LGE, in this study, resembled the more common
CAD pattern and indicated possibly a single event
with a larger embolus than seen after coronary
interventions. It was not clear whether the patients
were enrolled consecutively or chosen selectively
from their entire cohort; and thus, the likely size of
the problem among all patients with PFO and
cryptogenic strokes, remains unclear. Bubble shunts
were severe (in 80% of patients) and atrial septal
aneurysm was present in 64% of the subjects.
Even with the caveats mentioned, this article is an
important contribution to the PFO literature. It adds
to the growing body of evidence that a PFO has
multiple, potentially adverse, consequences that are
often not noticed. Although a plethora of literature
addresses stroke in patients with a PFO, no systematic
study has evaluated embolism in other organ systems.
Although occasional reports of systemic embolism do
exist, they are not very common. Emboli often tend to
be small, and in many instances may be clinically
silent, and only detected (5) at pathology. Our failure
to detect these, in say the kidney or the heart, might be
a limitation of our methods, particularly in asymptom-
atic subjects and may require wider use of sophisti-
cated imaging methods. Recent data suggest that
diffusion-weighted CMR can reveal many silent cen-
tral nervous system emboli in patients with a PFO and
a pulmonary embolism (6). Thus, cardiac damage,
presumably from paradoxical emboli in the current
study, is more confirmatory data that a PFO may
allow multi-organ embolization. Unfortunately, this
investigation did not provide longer term follow-up
data and it would be very interesting to study the
significance of these small foci of LGE. Minor cardiac
injury, evidenced by troponin leaks and often regarded
as unimportant in the past, has significant influence
on long-term morbidity and mortality (e.g., after
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841oronary intervention and in chronic heart failure).
he potential threat of a PFO would be much greater
f there was a longer term downside to foci of minor
GE. Lack of a control group in this study makes it
ven harder to gauge the importance of LGE. One
ould expect a very low prevalence of LGE in this age
roup with no cardiac history. However non-CAD–
elated factors, such as vigorous exercise, influence
GE. One study (7) found up to a 4% prevalence of
GE in presumably healthy controls (57  6 years)
resenting for screening. The timing of the LGE
tudy is important. Device clots and nearly a 9% rate
f subclinical central nervous system emboli (8) were
escribed in the periprocedural period, and these too
ould have influenced cardiac LGE if both closure and
MR were done in close temporal proximity. Finally,
he group as a whole was at higher risk of emboliza-
ion with severe shunting and high prevalence of atrial
eptal aneurysm (9,10). We should, therefore, be
areful about generalizing these findings to the garden
ariety PFO population.
Second, given the additional reason to consider
FOs to be dangerous, the authors hint that cardiac
GE may be another reason to close a PFO in
atients with cryptogenic stroke. This contention,
lthough logical, is not supported by this study, and
xpanding indications for closure based on these
ypes of studies is premature. The PFO literature
as been full of controversy (11,12), circumstantial
vidence, and interventional recommendations,
ased solely on expert opinion. Physician unease
nd patient emotion about strokes (13) is often used
o justify aggressive interventional therapy. Who
hould be treated and how, are not based on strong,
igh-quality data and remain a matter of intense
ebate and opinion. Some studies question the
ssociation between PFO and strokes (14,15).
oreover cryptogenic stroke patients receiving
edical treatment have similar rates of recurrent
vents, whether they have a PFO or not (16) and a
ecent meta-analysis confirms this (17). Finally, a
hird of the PFOs may be an innocent bystander in
atients with cryptogenic stroke (18). Thus, al-
hough the risk of a PFO remains uncertain, there
s a small but finite risk to closures, even in
xperienced hands (19); some adverse events such as
n increased incidence of atrial fibrillation (20)
ight even make the embolic risk a bit higher. Thevident until we complete good-quality randomized
linical trials but our track record in doing this is
ot very encouraging (21); many physicians seem to
ave made up their minds about the right course of
ction and find it easier to just perform “off-label”
FO closure. It is, therefore, clearly not prudent to
se “2-territory embolization,” detectable only with
igh-quality imaging, as an indication to intervene
n patients with PFOs at this time. Nearly 40% of
schemic strokes in younger patients have no iden-
ifiable cause (22) and nearly half of these patients
ave an associated PFO (23). More sophisticated
maging (24,25) will identify even more patients
ho might be offered closure under this new para-
igm. Clearly, we have not reached that level of
vidence even in PFO and cryptogenic stroke, let
lone in anything even more expansive. We need to
ait for high-quality data before recommending
his option.
This neat study, with intriguing evidence of
aradoxical embolism into the heart, adds to the
ascinating story of PFOs and their adverse impact.
t also encourages the introduction of better imag-
ng to detect currently unidentified pathology. Any
eeper conclusion, especially regarding therapy,
ust await more data. A similar study with appro-
riate controls and longer term outcome data for
ny marker of subclinical embolization might be a
ood start. Whether we ever use such a paradigm
or introducing interventional therapy should de-
end on a much higher level of proof.
ddendum
ince this paper was submitted, the Closure I trial, a
andomized study comparing PFO closure with
TARFlex versus current medical therapy, failed to
how any significant benefit for PFO closure on
reventing recurrent TIA or strokes (NMT Medical
ress Release: Preliminary results of CLOSURE I
FO/stroke trial; Business Wire: June 17, 2010).
ore complete trial data were unavailable at this time
nd are expected to be released later this year. A
umber of other trials, however, are continuing and
ill provide a clearer picture down the road.
eprint request and correspondence:Dr. Y. Chandrashekhar,
ivision of Cardiology (111C), University of Minnesota, 1
eterans Drive, Minneapolis, Minnesota 55417. E-mail:xact risk-benefit ratio of closing a PFO will not be shekh003@umn.edu.
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